Chimerix Investor Conference Presentation Deck
●
✓
ONC201 Activity in Non-Midline H3 K27M Diffuse Glioma
Two of five patients had objective responses by RANO-HGG per investigator but not BICR¹
Both patients had a response by RANO-LGG per BICR
o Patients were on-treatment for 14 and 23 months
Responses were associated with increased mobility and alertness
Suggest activity may not be restricted by location
30
Change from baseline in SPD (%)
100 -
75
50 -
25
0
-25
-50
-75-
-100
0
T
1
Measured by RANO HGG²
3
5 6 7
Time from first dose (mo)
8 9 10 11 12 13 14 15 16 17 18
1.
Odia et al, SNO 2021
2. One of these five patients did not have a measurable lesion per BICR
Change from baseline in SPD (%)
100
75-
50
-50
-75-
-100
T
Measured by RANO LGG
T
T
5 6 7 8 9 10 11 12 13 14 15 16 17 18
Time from first dose (mo)
O 2021 Chimerix, IncView entire presentation